Video

Dr. Nelson on the Future Utility of ctDNA in CRC

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the future utility of circulating tumor (ct)DNA in colorectal cancer (CRC).

ctDNA is the future of CRC, says Nelson. The data that have been published on the use of ctDNA in CRC show curves that are widely separated, adds Nelson. Thesee data also indicate that ctDNA is a very powerful tool to detect minimal residual disease in these patients.

There is no question that this approach will be a very important component of clinical practice in the future, but exactly how it will be utilized remains unclear, concludes Nelson.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD